title: Ganciclovir - Neonatal Intensive Care Drug Manual
text: |
  Neonatal Intensive Care Drug Manual
  |
  bet | 231/654 | Sana | 03.01.2022 | Hajmi | 1,5 Mb. | | #14803 |
  Ganciclovir
  Revision Date : 10-12-2020
  |
  Approved : TC, KOH
  |
  Alert
  |
  High risk medicine. Cytotoxic agent.
  |
  Indication
  |
  Treatment of severe or moderately severe, symptomatic congenital CMV
  Treatment of acute severe CMV disease.
  |
  Action
  |
  Synthetic nucleoside analogue of 2-deoxyguanosine that inhibits replication of herpes viruses such as cytomegalovirus, herpes simplex virus 1 and 2, herpes virus type 6, 7 and 8, Epstein-Barr virus, varicella zoster virus and hepatitis B virus.
  |
  Drug type
  |
  Antiviral
  |
  Trade name
  |
  Cymevene, Ganciclovir SXP
  |
  Presentation
  |
  500 mg ganciclovir sodium vial for reconstitution
  |
  Dose
  |
  6 mg/kg/dose 12 hourly.
  Infants may be switched to oral valganciclovir if clinically stable and able to take oral medications.
  IV ganciclovir should generally not be used for more than 6 weeks.
  Please note, oral valganciclovir is the oral prodrug of ganciclovir and prescribed at a different dose.
  |
  Dose adjustment
  |
  |
  Maximum dose
  |
  |
  Total cumulative dose
  |
  |
  Route
  |
  IV
  |
  Preparation
  |
  IV Provided by pharmacy of the reconstituted/pre-diluted product. Final concentration should not be higher than 10 mg/mL. Cytotoxic agent so infusion should not be manipulated on the ward.
  |
  Administration
  |
  IV
  Follow full cytotoxic precautions as per local policy.
  IV infusion over 30 minutes preferably via central venous access.
  |
  Monitoring
  |
  Full blood count, particularly neutrophils, should be followed weekly for 6 weeks, then at week 8, then monthly for the duration of therapy.
  IV site for phlebitis
  Liver function tests monthly throughout therapy.
  Renal function tests.
  |
  |
  |
  | |